| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | -38.81% | — | — | — | — | — | — | — | — | — | -5019.95% |
| EBITDA Margin | — | -38.26% | — | — | — | — | — | — | — | — | — | -4828.07% |
| Net Margin | — | -49.43% | — | — | — | — | — | — | — | — | — | -5062.44% |
| Current Ratio | 0.31 | 0.11 | 0.07 | 0.87 | 4.37 | 2.63 | 4.89 | 6.45 | 7.16 | 1.23 | 4.79 | 3.96 |
| Quick Ratio | 0.31 | 0.11 | 0.07 | 0.87 | 4.37 | 2.63 | 4.89 | 6.45 | 7.16 | 1.23 | 4.79 | 3.96 |
| Debt / Equity | -0.08 | -0.27 | -0.17 | -1.18 | 0.54 | 1.14 | 0.41 | — | — | — | — | — |
| ROE | 50.35% | 12.92% | 75.46% | 338.32% | -298.10% | -338.00% | -140.49% | -109.96% | -99.31% | -1614.26% | -52.40% | -33.56% |
| ROA | -113.76% | -105.61% | -996.14% | -170.74% | -147.83% | -130.59% | -86.30% | -93.03% | -85.60% | -314.80% | -32.77% | -27.67% |
| Asset Turnover | 0.00 | 2.14 | 0.00 | — | — | — | — | — | — | — | — | 0.01 |
| Book Value / Share | -10.61 | -71.22 | -96.70 | -54.13 | 5630.97 | — | — | — | — | — | — | 44170.87 |
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare disease and other serious conditions. The company’s current work centers on small-molecule genetic therapies, with lead programs aimed at addressing Alport syndrome, a rare kidney disorder, and additional research directed toward cancer and inflammatory diseases. Eloxx Pharmaceuticals applies proprietary technology platforms to discover and advance product candidates designed to modulate disease pathways and support human therapeutic applications. The company operates within the biotechnology sector, where its role is to translate scientific research into potential treatment options for unmet medical needs. Eloxx Pharmaceuticals, Inc. is headquartered in the United States and remains focused on advancing its current pipeline and platform-based drug development efforts.